I'ROM GROUP CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,766 JPY | -0.04% |
|
+0.04% | +37.68% |
| May. 31 | GenoDive Pharma Inc announced that it has received funding from I'rom Group Co., Ltd. | CI |
| 2023 | I'rom Group Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 | CI |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 17,495 | 15,390 | 29,466 | 23,271 | 22,908 | 22,871 |
| Enterprise Value (EV) 1 | 19,754 | 18,996 | 34,639 | 30,264 | 32,031 | 34,164 |
| P/E ratio | 20 x | 12.5 x | 21.4 x | 11.9 x | 9.01 x | 16.2 x |
| Yield | 1.32% | 3.07% | 1.64% | 2.08% | 2.64% | - |
| Capitalization / Revenue | 1.65 x | 1.45 x | 2.28 x | 1.48 x | 1.25 x | 1.29 x |
| EV / Revenue | 1.87 x | 1.79 x | 2.68 x | 1.93 x | 1.75 x | 1.93 x |
| EV / EBITDA | 13.8 x | 12.1 x | 22.1 x | 9.64 x | 7.46 x | 15 x |
| EV / FCF | -13 x | -14.1 x | -12.1 x | 79.8 x | 35 x | -10.6 x |
| FCF Yield | -7.68% | -7.1% | -8.24% | 1.25% | 2.86% | -9.45% |
| Price to Book | 2.87 x | 2.15 x | 3.39 x | 2.29 x | 1.89 x | 1.79 x |
| Nbr of stocks (in thousands) | 11,556 | 11,820 | 12,057 | 12,076 | 12,108 | 12,108 |
| Reference price 2 | 1,514 | 1,302 | 2,444 | 1,927 | 1,892 | 1,889 |
| Announcement Date | 6/26/19 | 6/25/20 | 6/28/21 | 6/28/22 | 6/28/23 | 6/26/24 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net sales 1 | 10,578 | 10,593 | 12,906 | 15,693 | 18,351 | 17,740 |
| EBITDA 1 | 1,435 | 1,571 | 1,564 | 3,139 | 4,296 | 2,271 |
| EBIT 1 | 1,221 | 1,208 | 1,069 | 2,532 | 3,499 | 1,135 |
| Operating Margin | 11.54% | 11.4% | 8.28% | 16.13% | 19.07% | 6.4% |
| Earnings before Tax (EBT) 1 | 1,178 | 1,127 | 1,686 | 2,586 | 3,342 | 1,966 |
| Net income 1 | 912 | 1,236 | 1,373 | 1,961 | 2,542 | 1,415 |
| Net margin | 8.62% | 11.67% | 10.64% | 12.5% | 13.85% | 7.98% |
| EPS 2 | 75.75 | 104.3 | 114.0 | 162.2 | 210.1 | 116.9 |
| Free Cash Flow 1 | -1,517 | -1,348 | -2,853 | 379.1 | 915.6 | -3,227 |
| FCF margin | -14.34% | -12.73% | -22.1% | 2.42% | 4.99% | -18.19% |
| FCF Conversion (EBITDA) | - | - | - | 12.08% | 21.31% | - |
| FCF Conversion (Net income) | - | - | - | 19.33% | 36.02% | - |
| Dividend per Share 2 | 20.00 | 40.00 | 40.00 | 40.00 | 50.00 | - |
| Announcement Date | 6/26/19 | 6/25/20 | 6/28/21 | 6/28/22 | 6/28/23 | 6/26/24 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 S1 | 2022 S1 | 2022 Q3 | 2023 Q1 | 2023 S1 | 2023 Q3 | 2024 Q1 | 2024 S1 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5,078 | 6,839 | 4,837 | 4,792 | 9,639 | 4,257 | 4,659 | 8,678 | 4,190 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 351 | 858 | 1,339 | 1,449 | 2,409 | 618 | 737 | 790 | 20 |
| Operating Margin | 6.91% | 12.55% | 27.68% | 30.24% | 24.99% | 14.52% | 15.82% | 9.1% | 0.48% |
| Earnings before Tax (EBT) 1 | 459 | 1,022 | 1,336 | 1,492 | 2,565 | 415 | 1,179 | 1,414 | -77 |
| Net income 1 | 319 | 723 | 1,055 | 1,067 | 1,983 | 255 | 891 | 1,092 | -120 |
| Net margin | 6.28% | 10.57% | 21.81% | 22.27% | 20.57% | 5.99% | 19.12% | 12.58% | -2.86% |
| EPS 2 | 26.68 | 59.99 | 87.39 | 88.37 | 164.2 | 20.96 | 73.66 | 90.22 | -9.890 |
| Dividend per Share | 20.00 | 20.00 | - | - | 25.00 | - | - | 40.00 | - |
| Announcement Date | 11/5/20 | 11/4/21 | 2/3/22 | 8/4/22 | 11/2/22 | 2/7/23 | 8/4/23 | 11/6/23 | 2/7/24 |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 2,259 | 3,606 | 5,173 | 6,993 | 9,123 | 11,293 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 1.574 x | 2.295 x | 3.308 x | 2.228 x | 2.124 x | 4.973 x |
| Free Cash Flow 1 | -1,517 | -1,348 | -2,853 | 379 | 916 | -3,227 |
| ROE (net income / shareholders' equity) | 15.2% | 18.7% | 17.3% | 20.7% | 22.9% | 11.4% |
| ROA (Net income/ Total Assets) | 6.16% | 5.28% | 3.71% | 6.67% | 7.09% | 1.96% |
| Assets 1 | 14,808 | 23,426 | 36,984 | 29,417 | 35,870 | 72,087 |
| Book Value Per Share 2 | 528.0 | 606.0 | 722.0 | 840.0 | 1,003 | 1,055 |
| Cash Flow per Share 2 | 258.0 | 207.0 | 337.0 | 530.0 | 775.0 | 598.0 |
| Capex 1 | 1,867 | 1,401 | 2,636 | 2,042 | 4,167 | 4,025 |
| Capex / Sales | 17.65% | 13.23% | 20.42% | 13.01% | 22.71% | 22.69% |
| Announcement Date | 6/26/19 | 6/25/20 | 6/28/21 | 6/28/22 | 6/28/23 | 6/26/24 |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +37.68% | 208M | |
| -19.11% | 8.35B | |
| +69.83% | 4.36B | |
| +13.47% | 2.9B | |
| -2.45% | 2.64B | |
| -15.27% | 1.75B | |
| -59.82% | 1.61B | |
| -16.57% | 1.5B | |
| +21.70% | 1.25B | |
| -50.86% | 997M |
- Stock Market
- Equities
- 2372 Stock
- Financials I'rom Group Co., Ltd.
